In addition, a comprehensive critical review encompassing 21 studies concluded that overall survival outcomes were worse for NSCLC patients with SMARCA4 mutations than those with wild-type SMARCA4 alleles (tumors without SMARCA4 mutations) [16]. Here, SMARCA4 is linked to non-small cell lung carcinoma.